Marksans Pharma Ltd. announced its audited financial results for the fiscal year ending March 31, 2026, on May 26, 2026. The Board of Directors approved the standalone and consolidated financial statements, which received an unmodified opinion from auditors MSKA & Associates LLP. The company also recommended a final dividend of ₹0.90 per equity share for FY 2025-26, subject to shareholder approval at the upcoming AGM.
Marksans Pharma Ltd. Announces FY26 Financials and Dividend Recommendation
On May 26, 2026, Marksans Pharma Ltd. officially communicated the outcome of its Board of Directors’ meeting, where the audited financial results for the quarter and year ended March 31, 2026, were approved. The company submitted both standalone and consolidated financial results, along with the auditors’ reports, to the stock exchanges.
Audited Financial Results Approved
The Board of Directors of Marksans Pharma Limited has given its approval to the audited financial results for the fiscal year ending March 31, 2026. The independent auditors, MSKA & Associates LLP, have provided an unmodified opinion on these results, confirming their accuracy and fairness. This includes both the standalone and consolidated financial statements.
Final Dividend Recommendation
A significant highlight of the board meeting was the recommendation of a final dividend. The Board has proposed a dividend of ₹0.90 per equity share, representing 90% of the face value of ₹1 per share, for the financial year 2025-26. This dividend is contingent upon the approval of the company’s shareholders at the forthcoming Annual General Meeting (AGM) and will be credited or dispatched within 30 days of the AGM.
Information Availability
The information regarding the board meeting outcome and the audited financial results is made available to the public on the company’s official website, www.marksanspharma.com, as well as on the websites of the BSE and NSE, where the company’s shares are listed.
Meeting Details
The Board meeting, which commenced at 11:55 AM, concluded at 12:45 PM on May 26, 2026.
Key Financial Highlights (Standalone – FY 2025-26)
- Revenue from operations: ₹13,414.76 million
- Total Income: ₹14,450.09 million
- Total Expenses: ₹10,534.66 million
- Profit Before Tax: ₹3,915.43 million
- Profit After Tax: ₹3,006.98 million
- Total Comprehensive Income: ₹3,017.39 million
- Earnings Per Equity Share (Basic): ₹6.64
Key Financial Highlights (Consolidated – FY 2025-26)
- Revenue from operations: ₹29,509.38 million
- Total Income: ₹30,334.71 million
- Total Expenses: ₹24,729.16 million
- Profit Before Tax: ₹5,605.55 million
- Profit After Tax: ₹4,200.64 million
- Total Comprehensive Income: ₹5,962.12 million
- Earnings Per Equity Share (Basic): ₹9.22
Source: BSE
